Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
05:00am, Monday, 27'th Apr 2026
NEW YORK, April 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and D
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 26'th Apr 2026
New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on be
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 24'th Apr 2026
New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights
05:25pm, Thursday, 23'rd Apr 2026
SAN DIEGO--(BUSINESS WIRE)---- $NKTR #Nektar--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ
SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closi
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Thursday, 23'rd Apr 2026
LOS ANGELES, April 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportu
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
09:50am, Thursday, 23'rd Apr 2026
LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
The Red Flags: What Insiders Allegedly Knew Before Shareholders Did NEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Nektar Therapeuti
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
08:01am, Thursday, 23'rd Apr 2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
New York, New York--(Newsfile Corp. - April 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA NEW YORK, April 22, 2026 /PRNewswire/ -- IMPORTANT DATE: May 5, 2026. Investors who purchased Nektar Therapeutics (NASDAQ: NKTR)
